Background. Fluorodeoxyglucose-positron emission tomography (FDG-PET) is recommended for diagnosis and staging of non-small cell lung cancer (NSCLC). Metaanalyses of FDG-PET diagnostic accuracy demonstrated sensitivity of 96% and specificity of 78% but were performed in select centers, introducing potential bias. This study evaluates the accuracy of FDG-PET to diagnose NSCLC and examines differences across enrolling sites in the national American College of Surgeons Oncology Group (ACOSOG) Z4031 trial.
Background. Fluorodeoxyglucose-positron emission tomography (FDG-PET) is recommended for diagnosis and staging of non-small cell lung cancer (NSCLC). Metaanalyses of FDG-PET diagnostic accuracy demonstrated sensitivity of 96% and specificity of 78% but were performed in select centers, introducing potential bias. This study evaluates the accuracy of FDG-PET to diagnose NSCLC and examines differences across enrolling sites in the national American College of Surgeons Oncology Group (ACOSOG) Z4031 trial.
Methods. Between 2004 and 2006, 959 eligible patients with clinical stage I (cT1-2 N0 M0) known or suspected NSCLC were enrolled in the Z4031 trial, and with a baseline FDG-PET available for 682. Final diagnosis was determined by pathologic examination. FDG-PET avidity was categorized into avid or not avid by radiologist description or reported maximum standard uptake value. FDG-PET diagnostic accuracy was calculated for the entire cohort. Accuracy differences based on preoperative size and by enrolling site were examined.
Results. Preoperative FDG-PET results were available for 682 participants enrolled at 51 sites in 39 cities. Lung cancer prevalence was 83%. FDG-PET sensitivity was 82% (95% confidence interval, 79 to 85) and specificity was 31% (95% confidence interval, 23% to 40%). Positive and negative predictive values were 85% and 26%, respectively. Accuracy improved with lesion size. Of 80 false-positive scans, 69% were granulomas. False-negative scans occurred in 101 patients, with adenocarcinoma being the most frequent (64%), and 11 were 10 mm or less. The sensitivity varied from 68% to 91% (p [ 0.03), and the specificity ranged from 15% to 44% (p [ 0.72) across cities with more than 25 participants.
Conclusions. In a national surgical population with clinical stage I NSCLC, FDG-PET to diagnose lung cancer performed poorly compared with published studies.
(Ann Thorac Surg 2014;97:1142-8) Ó 2014 by The Society of Thoracic Surgeons T he National Lung Screening Trial (NLST) recently reported that a screening regimen of annual low-dose computed tomography (CT) scans reduced lung cancerrelated mortality by 20% in a high-risk population. The United States Preventive Services Task Force, physician societies, and patient advocate groups have recommended lung cancer screening using low-dose CT scans for high-risk populations [1] [2] [3] [4] [5] [6] . Although lung cancerrelated mortality in the NLST was reduced, 96% of lung abnormalities found by CT were false-positive findings [2] . Other studies found similarly high rates of false-positive results [7, 8] . These false-positive results required additional radiographic and procedural tests to confirm a diagnosis or rule out lung cancer.
The American College of Chest Physicians and National Comprehensive Cancer Network guidelines recommend using fluorodeoxyglucose-positron emission tomography (FDG-PET) scans to help diagnose pulmonary nodules sized larger than 8 mm that do not exhibit significant benign characteristics and have a low to moderate risk for malignancy [1, 9] . Meta-analysis of the diagnostic accuracy of FDG-PET reported 96% sensitivity and 78% specificity [10] , but recent studies have questioned the generalizability of these results to regions of the country with endemic fungal lung disease [11, 12] .
The recently concluded American College of Surgeons Oncology Group (ACOSOG) Z4031 trial evaluated patients with known or suspected clinical stage I non-small cell lung cancer (NSCLC). This trial obtained FDG-PET results, providing a large national sample to determine the accuracy of FDG-PET to diagnose early-stage lung cancer in a population undergoing surgical resection. We conducted a secondary analysis of the ACOSOG trial to determine the diagnostic accuracy of FDG-PET to diagnose lung cancer in patients with known or suspected clinical stage I lung cancer being evaluated for surgical intervention and examine whether the test's accuracy varied between study sites.
Patients and Methods
This secondary analysis of the ACOSOG Z4031 study was approved by the Vanderbilt Investigational Review Board.
Population
The primary objective of the ACOSOG Z4031 study "Use of Proteomic Analysis of Serum Samples for Detection of Non-Small Cell Lung Cancer" (5U10CA076001-11) was to determine prospectively whether a serum proteomic profile could predict the presence of primary NSCLC in patients with suspicious lung lesions who were candidates for lung resection. The study design was a prospective study of 1,000 patients undergoing lung resection for clinically suspicious lung lesions. The ACOSOG trial was a national study that occurred across 23 states and Ontario, Canada, in 51 hospitals located in 39 different cities (Fig 1) . Patients were enrolled in the ACOSOG Z4031 trial from February 2004 to May 2006. Inclusion criteria were (1) age 18 years or older, (2) clinically suspicious stage I lung lesion, (3) CT scan within 60 days before the lung resection and no evidence of metastatic disease, (4) no untreated malignancies, (5) asymptomatic survival exceeding 5 years if prior malignancy, and (6) able to provide informed consent. Exclusion criteria included patients who had (1) undergone lung resection within the preceding 30 days, (2) received prior chemotherapy or radiotherapy, and (3) received a blood product transfusion of any kind within the past 60 days of the operative procedure [13] . The ACOSOG Z4031 prospective clinical trial contains data on 969 patients who met all of the eligibility criteria.
Preoperative FDG-PET scans were not required for all participants, and clinician report of the scan was included in addition to the most recent preoperative CT scan as part of the study protocol. FDG-PET and combined FDG-PET/CT scans were both conducted at the discretion of the physician. The type of FDG scan (PET or PET/CT) was based on the institution availability. No original scans were available for review.
Data Collection
Data collected at enrollment were age, sex, race, ethnicity, body mass index, date of operation, clinical stage, CT reports, FDG-PET reports, enrolling site, and zip code or postal code of the patient residence. Operative notes and pathologic reports were collected along with 30-day mortality status, status at last follow-up, date of the last follow-up, and cause of death if dead at the last follow-up. Follow-up for the study participants was 5 years. All data were stored and maintained by the ACOSOG data center.
Additional data were abstracted from the study case report forms, including clinical maximum lesion diameter according to CT or PET/CT immediately before resection, smoking status, pack-years, FDG-PET scan before operation, pathologic result for benign disease, FDG-PET scan result, and standard uptake value (SUV), when provided. Data were extracted from case report forms by trained medical reviewers. FDG-PET scan results were categorized from the radiologist descriptor of avidity or maximum SUV. The two categories were "not avid" if the report contained not avid/not cancerous, low avidity/ not likely cancerous, or SUV of less than 2.5 when reported and "avid" if the report contained avid/likely cancerous, highly avid/cancerous, or SUV of 2.5 or more. Pathologic reports and operative notes were reviewed to determine etiology of benign disease and the specific cancer diagnosis.
Analysis
Differences in the demographics between the participants with benign and malignant lesions were compared using a t test for continuous variables (age and lesion size) and a binomial proportions test for differences in proportions (sex, race, and FDG-PET avidity). Sensitivity, specificity and positive and negative predictive values were calculated for the study population who had FDG-PET scans. The FDG-PET accuracy to diagnose lung cancer equals true positives plus true negatives divided by the population tested and was calculated using the pathologic diagnosis as the reference. The sensitivity and specificity was calculated separately for those cities with greater than 25 participants. Differences in the sensitivity and specificity between cities were estimated using the c 2 statistic. The accuracy of FDG-PET grouped by lesion size was compared with an analysis of variance for patients with FDG-PET scans.
Results
Our current study had 682 participants who met the ACOSOG Z4031 trial eligibility criteria and had a preoperative FDG-PET scan ( Table 1) . As determined by the pathologic reports provided by the home institution, benign disease was found in 116 patients (17%) and cancer in 566 (83%). Microbiologic results abstracted from pathologic or operative reports resulted in only 11% of benign cases having an unknown diagnosis. Of the 116 benign patients, 75 (65%) were documented in the pathologic report as being granulomatous and 30 (26%) of the granulomas had documented histoplasmosis etiology in the pathologic report (Table 2) . Patients with cancer were more likely to be older, non-Caucasian, and have larger lesions that were FDG-PET avid than patients with benign disease. The overall accuracy of FDG-PET to diagnose lung cancer was 73% compared with the pathologic diagnosis. The sensitivity was 82% and specificity was 31%, and the positive and negative predictive values were 85% and 26%, respectively (Table 3) . Of the 80 false-positive results, 69% of these were granulomas (Table 4) . Of the 101 false-negative results, 11 lesions were sized 1 cm or less, and 62% of these were adenocarcinoma, 11% were squamous, 10% were carcinoma in situ, and 9% were neuroendocrine. Most patients with false-positive FDG-PET scans had granulomas and most of those with falsenegative FDG-PET scan results had adenocarcinoma.
There were 8 cities with more than 25 participants (Table 5) , and these comprised 462 of the 682 patients (68%). The observed sensitivity by city varied from 68% to 91% (p ¼ 0.03), and the specificity ranged from 15% to 44% (p ¼ 0.72). FDG-PET accuracy improved with lesion size (Fig 2) from 67% in lesions that were sized 1 to 2 cm (sensitivity, 76%; specificity, 35%) to 84% in lesions that were sized 3 to 5 cm (sensitivity, 90%; specificity, 18%; p<0.001).
Comment
A retrospective analysis of the ACOSOG Z4031 trial showed FDG-PET performed poorly, with a sensitivity of 82% and specificity of 31%. The positive predictive value was 85% and the negative predictive value was 26%. Most of the false-positive scans were granulomas and most of the false-negative scans were adenocarcinoma. Only 11% of false-negative scans occurred in lesions sized less than 1 cm. The accuracy in lesions sized less than 1 cm was 54%. In this population of clinical stage I disease, nearly half, 322 patients, had lesions 2 cm in diameter or smaller, and FDG-PET accuracy in these patients was 66%. The sensitivity varied across the 8 cities where more than 25 patients were enrolled. As expected, FDG-PET accuracy increased with lesion size until lesions were larger than 3 cm, where test accuracy remained constant with increasing size. Increasing age and preoperative lesion size were associated with a malignant diagnosis.
The poor results for FDG-PET to diagnose lung cancer reported in this study give insight to possible issues for this imaging modality if applied nationally to lung nodules arising from a screening population. The ACOSOG Z4031 study had participants from 17 cities that were also cities in the NLST. Pathologic stage IA disease was observed in 45% of the ACOSOG trial and in 40% of the NLST. Currently available FDG-PET scanners have limited ability to detect metabolically active lesions smaller than 7 to 8 mm, and FDG-PET is not recommended for lesions smaller than 1 cm due to high falsenegative rates [14, 15] . For lesions between 1 and 3 cm in diameter, a recent meta-analysis found FDG-PET was accurate (sensitivity, 94%; specificity, 83%) [16] . The much lower sensitivity observed in the ACOSOG trial may have been caused by this population having more lesions between 1 and 2 cm compared with those reported in other single-institution series. If more smaller lesions can be expected to arise from a screening population, then the sensitivity of FDG-PET may be more similar to that observed in our study than previously reported.
The sensitivity and specificity of FDG-PET to diagnose lung cancer in this trial was similar to two previously reported surgical series from Iowa City, Iowa, and Nashville, Tennessee. Both regions have a high prevalence of fungal lung disease. Croft and colleagues [12] reported a sensitivity of 93% and specificity of 40% in their smaller, Midwest cohort, with all imaging performed at a tertiary referral center. Deppen and colleagues [11] reported a sensitivity of 92% and specificity of 40% in a patient population predominantly from the South Central United States, with imaging performed at a variety of regional imaging centers. Both locations noted having a high prevalence of endemic fungal lung disease, and granulomas were the most common benign results observed in each of those studies.
The current study also had a preponderance of granulomas (69% of false-positive FDG-PET results). Fungal lung disease occurs broadly across Mississippi, Ohio, the lower Missouri and Tennessee River Valley regions, as well as southern Ontario, as histoplasmosis and blastomycosis. Coccidioidomycosis is prevalent across the Southwest, from west Texas through New Mexico, Arizona, and the San Joaquin Valley in California [17] . Higher rates of granulomatous disease can be expected from these geographic areas as well.
The results of our study question the usefulness of FDG-PET to diagnose lung cancer in regions with endemic fungal lung disease. Further studies should be performed to determine the most cost-effective strategy to diagnose lung cancer comparing FDG-PET with bronchoscopic and CT-guided fine-needle aspirations.
The results from this study differ from prior metaanalyses by Gould and colleagues [10] , who reported a sensitivity of 96% and specificity of 78%, and by Cronin and colleagues [16] , who report similar results (95% sensitivity and 82% specificity) for combined FDG-PET/ CT scans. The differences in our current report from these two studies may arise from a number of factors. First, verification bias is likely present in our current study due to the entire ACOSOG population having a pathologic diagnosis after surgical resection. Verification bias arises when a diagnostic test is used to help determine who receives the gold standard for diagnosis or, in this instance, who is likely to be included in the study. When verification bias occurs, the population measured is more likely to have positive test results (true positives and false positives), and less likely to have negative test results (true negatives and false negatives). Verification bias generally results in a diagnostic test having higher sensitivity due to fewer false negatives being included and lower specificity due to more false positives being included in a study population. Verification bias may explain the observed low specificity but does not explain the lower sensitivity in this study compared with previous reports [18] . The population of patients in our current study may also be different from the meta-analyses. The inclusion criteria of the Z4031 trial required clinical stage I disease before surgical resection so patients with PET-avid mediastinal lesions were excluded or required invasive mediastinal staging. Other single-institution series used in metaanalysis include those with known or suspected lung cancer, as well as all prediagnosis clinical stages. A large number of sites contributing patients in the ACOSOG study are in regions of the United States with a high prevalence of fungal lung disease; and consequently, a large number of granulomas were observed in this series. This was not true for the sites used in the meta-analyses.
Finally, the FDG-PET scans in the ACOSOG study were performed at many different institutions as well as at community imaging centers and by many different clinicians. This lack of uniformity of test administration introduces variability in scanning quality and interpretations by the clinicians. The meta-analyses evaluated cohorts where the FDG-PET scans were typically performed at the reporting academic institution. Overall, our current study reports a reduced overall accuracy of FDG-PET to diagnose lung cancer compared with published results.
Our study is one of the largest series evaluating the accuracy of FDG-PET to diagnose lung cancer in clinical stage I disease and represents a national sample with more than 650 patients from 39 cities in the United States. Cancer or benign disease was determined pathologically because all patients underwent a surgical resection. Because it is a clinical study in a large national sample from multiple institutions with multiple surgeons and interpreting radiologists, the results are generalizable to clinical practice for early-stage patients being evaluated for surgical resection.
However, because our study represents a secondary analysis of a clinical trial, biases associated with retrospective reviews of the FDG-PET results are possible. To reduce these biases, reviewers were used who had experience with these types of record reviews, were blinded to the final pathology and staging, and did not conduct the analyses. Because FDG-PET scans were performed at multiple academic and community centers, there were no standard FDG-PET scan administration or interpretation protocols. For example, maximum SUV was reported in 461 patients (67.6%), and 101 (22%) reporting maximum SUV were from a single institution, preventing us from performing meaningful analyses using this continuous variable.
We believe that variability of FDG-PET administration is both a strength and a weakness of the study because it increases the generalizability of the study nationally, but the results may not be applicable to high-volume centers with expertise in FDG-PET scans. We chose to analyze variability of FDG-PET accuracy at the city level as a method of aggregating data from a relatively homogeneous geographic region. Further analyses are ongoing to determine FDG-PET variability at the patient level.
In addition, this study does not address the role of the FDG-PET scan for clinical staging of lung cancer. Because original scans were not available, reviewers were unable to consistently determine whether a scan was a FDG-PET-only scan, which is less accurate than a combined FDG-PET/CT scan. Finally, FDG-PET technology is continuously improving, and the scans used in this study were performed 7 to 9 years ago.
In conclusion, the accuracy of the FDG-PET scan to diagnose lung cancer in a national sample of patients with known or suspected clinical stage I NSCLC is less than the accuracy in previously reported meta-analyses. Results of FDG-PET should be interpreted cautiously when diagnostic or treatment decisions are being made for patients with suspicious pulmonary lesions. Further research is needed to determine the effect of fungal lung disease on false-positive FDG-PET results. For the surgeon evaluating smaller or screening-discovered lesions in a population with a high prevalence of disease, future diagnostic test development should focus on minimization of falsenegative results and improved negative predictive value when adenocarcinoma, carcinoid, or carcinoma in situ tumors are suspected.
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